Yi Zhao
No. 168 Litang Road
Changping, 102218, China
Changping, 102218, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
3D-Printed lesion-conformal light-guiding patches for precise and personalized psoriasis phototherapy.
Journal: Biomaterials science
Published: April 24, 2026
HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.
Journal: Dermatology and therapy
Published: January 14, 2026
Increased risk of superficial fungal infections with interleukin 17 inhibitors in psoriasis vulgaris: A retrospective cohort study.
Journal: Journal of the American Academy of Dermatology
Published: December 24, 2025
Risk of type 2 inflammation-related diseases during interleukin-17 inhibitor treatment for patients with psoriasis: a retrospective cohort study.
Journal: The British journal of dermatology
Published: October 13, 2025
A pilot randomized split-face trial comparing fractional Q-Switched ruby laser and 1064-nm Q-Switched nd: YAG laser in Chinese women with melasma running titile: fQSRL vs. QSNY in melasma.
Journal: Lasers in medical science
Published: May 12, 2025
Comprehensive management: Paradigm shift of care for psoriasis.
Journal: Chinese medical journal
Published: April 30, 2025
Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis.
Journal: Clinical, cosmetic and investigational dermatology
Published: December 16, 2024
NDRG2 Deficiency Exacerbates UVB-Induced Skin Inflammation and Oxidative Stress Damage.
Journal: Inflammation
Published: April 07, 2024
Risk factors and early detection of joint damage in patients with psoriasis: a case-control study.
Journal: International journal of dermatology
Published: November 08, 2023
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Journal: The British journal of dermatology
Published: September 26, 2023
Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Journal: Chinese medical journal
Published: June 24, 2023
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Journal: International immunopharmacology
Published: May 31, 2022
Last Updated: 09/26/2026